Base Case
|
−48
|
-$683 107
|
1
|
A Dominates B
|
Vaccine price
|
HPV-6/11/16/18 vaccine price decreased to $98 per dose
|
−48
|
-$83 107
|
1
|
A Dominates B
|
HPV-6/11/16/18 vaccine price decreased to $97 per dose
|
−48
|
$216 893
|
1
|
$145 773 B lower lifetime cost; A saves more QALYs
|
HPV distribution
|
Changed to North American data
|
−41
|
-$760 577
|
−13
|
$59 359 A lower lifetime cost; B saves more QALYs
|
Proportion of 6 / 11 in genital warts increased to 90%
|
−48
|
-$496 855
|
−19
|
$26 015 A lower lifetime cost; B saves more QALYs
|
Impact of herd immunity on male genital wart lesions
|
Double incidence of GW, assume herd immunity impact of 20%
|
−48
|
-$564 421
|
−8
|
$68 100 A lower lifetime cost; B saves more QALYs
|
Double incidence of GW, assume herd immunity impact of 30%
|
−48
|
-$461 020
|
−18
|
$25 388 A lower lifetime cost; B saves more QALYs
|
Double incidence of GW, assume herd immunity impact of 40%
|
−48
|
-$355 588
|
−28
|
$12 629 A lower lifetime cost; B saves more QALYs
|
Double incidence of GW, assume herd immunity impact of 50%
|
−48
|
-$248 084
|
−38
|
$6 481 A lower lifetime cost; B saves more QALYs
|
Double incidence of GW, assume herd immunity impact of 90%
|
−48
|
$203 554
|
−80
|
B Dominates A
|
Incidence of GW*2.2, assume herd immunity impact of 20%
|
−48
|
-$538 277
|
−10
|
$52 037 A lower lifetime cost; B saves more QALYs
|
Incidence of GW*2.2, assume herd immunity impact of 30%
|
−48
|
-$414 878
|
−22
|
$18 739 A lower lifetime cost; B saves more QALYs
|
Incidence of GW*2.2, assume herd immunity impact of 40%
|
−48
|
-$288 911
|
−34
|
$8 473 A lower lifetime cost; B saves more QALYs
|
Incidence of GW*2.2, assume herd immunity impact of 50%
|
−48
|
-$160 318
|
−46
|
$3 468 A lower lifetime cost; B saves more QALYs
|
Incidence of GW*2.2, assume herd immunity impact of 90%
|
−48
|
$381 563
|
−96
|
B Dominates A
|
Genital warts incidence
|
+25%
|
−48
|
−449 523
|
−20
|
$22 485 A lower lifetime cost; B saves more QALYs
|
+10%
|
−48
|
−589 284
|
−7
|
$82 535 A lower lifetime cost; B saves more QALYs
|
−10%
|
−48
|
−777 456
|
10
|
A Dominates B
|
−25%
|
−48
|
−919 979
|
23
|
A Dominates B
|
Genital warts cost
|
Increased to 125% of base case
|
−48
|
-$444 754
|
1
|
A Dominates B
|
Decreased to 75% of base case
|
−48
|
-$924 966
|
1
|
A Dominates B
|
Genital warts disutility
|
Increased to 125% of base case
|
−48
|
-$683 107
|
−21
|
$32 749 A lower lifetime costs; B saves more QALYs
|
Decreased to 75% of base case
|
−48
|
-$683 107
|
24
|
A Dominates B
|
0.041, Drolet et al.
|
−48
|
-$683 107
|
−95
|
$7 170 A lower lifetime costs; B saves more QALYs
|